Macro Tsimmis

intelligently hedged investment

Vertex (VRTX) update #17

Posted by intelledgement on Wed, 24 Sep 08

Vertex (VRTX) stock rocketed up 16% today after the company released new data on their ongoing phase 2 trials of their anti-hepatitis C drug candidate, telaprevir. According to published reports, the data indicated that a two-dose-per-day regimen of telaprevir was just as effective as the three-dose-per-day regimen (at a lower dosage) that had been exclusively used up to now.

This is important for two reasons: [a] it is easier for patients to take a drug twice a day than three times a day and [b] some prospective competitors to telaprevir are designed for twice- or once-a-day dosing, which in the event any of them prove as effective, would have given that drug a big advantage if telaprevir required thrice-a-day dosing.


Leave a Reply

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: